Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a safety and pharmacokinetics study of luspatercept in pediatric beta-thalassemia requiring regular transfusions
2019-000208-13Phase 2Active
- Sponsor
- Celgene Corporation
- Start
- Jun 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of luspatercept in beta thalassemia, sponsored by Celgene Corporation. Primary endpoint: Determination of the Recommended Dose. Started Jun 2019; status: active.
02
Drugs
luspatercept
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on 2019-000208-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000208-13.